Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label study of Tiscover for chronic leg ulcers
NL-OMON27551Active, not recruiting
- Sponsor
- NWO-Biopartner First Stage Grant
- Start
- Oct 2005
- Modality
- Cell Therapies, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of Tiscover in leg ulcer, stasis ulcer, arterial leg ulcer and 1 more (4 arms), sponsored by NWO-Biopartner First Stage Grant. Primary endpoints: Ulcer size reduction and Complete healing. Started Oct 2005; status: active, not recruiting.
02
Drugs
Tiscover
03
Conditions
leg ulcerstasis ulcerarterial leg ulcerMixed venous-arterial leg ulcer (MVALU)
Beyond the preview
Go deeper on NL-OMON27551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27551.